In a quiet corner of the lung, where air meets blood, the cells that guard the airspaces may sometimes carry a hidden burden. A team at UCLA Health has shown in mice that when alveolar macrophages mishandle cholesterol and fat, the imbalance can help set pulmonary fibrosis in motion rather than merely trailing it as damage already done. For a disease that slowly hardens the lung and has long resisted explanation, this shifts the question from how to slow scarring to where the scarring begins. The evidence is still animal evidence, and its meaning for human patients awaits the test of time and
UCLA Mouse Study Links Lipid Imbalance in Lung Macrophages to Pulmonary Fibrosis Onset
Pulmonary fibrosis causes progressive lung scarring, respiratory failure, and high mortality, though the study itself involved only mice.
Fat-filled cells may be a cause of lung scarring, not just a sign of it
Mark
So what's actually new here? Fatty macrophages in fibrotic lungs aren't news.
Mimi
Right, they'd been seen before. The shift is the direction of cause. They were treated as fallout from the disease, and this study suggests they may help start it.
Mark
What's the evidence for that ordering?
Mimi
In mice lacking ABCG1, lipids, especially cholesterol, piled up in alveolar macrophages before other changes showed in the lungs. Then those lipids signaled fibroblasts to make scar tissue.
Luke
Let me hold that up to the light. Mice missing a protein entirely is a pretty blunt tool. Does it tell us this is what happens in human disease?
Mimi
It doesn't, and the reporting says as much. This is a mouse study, not yet tested in people.
Mark
The transplant experiments seem to matter, though.
Mimi
They do. Restoring ABCG1-carrying macrophages almost completely protected the mice, and ABCG1-deficient marrow in normal mice promoted fibrosis. It works in both directions.
Luke
Still, the article gives no numbers on how much fibrosis or how many animals. "Almost completely" is a description, not a measurement.
Mimi
Fair. We can't say more than what's stated.
Mark
And the practical hope?
Mimi
Treatments that protect lipid handling in macrophages, or block fibroblast uptake of lipids, and maybe earlier detection of risk. Those are possibilities, not products.
Luke
Possibilities is the right word. Nothing here says a therapy exists yet.
Der Puls
- A quiet imbalance of fat inside the lung's first-line immune cells may be igniting scarring that, until now, was seen mostly as an afterthought.
- Mice lacking the cholesterol-handling protein ABCG1 showed lipids piling up in alveolar macrophages before any visible fibrosis appeared.
- Those swollen macrophages can signal neighboring fibroblasts to activate and lay down scar tissue, linking lipid buildup directly to the disease.
- Restoring healthy macrophages through bone marrow transfer almost fully shielded the mice, while deficient marrow alone was enough to drive fibrosis.
- The path forward runs through preventive treatments and early lipid-based diagnostics, but the work has not yet been tested in human patients.
In a quiet corner of the lung, where air meets blood, the cells that guard the airspaces may sometimes carry a hidden burden. A team at UCLA Health has shown in mice that when alveolar macrophages mishandle cholesterol and fat, the imbalance can help set pulmonary fibrosis in motion rather than merely trailing it as damage already done. For a disease that slowly hardens the lung and has long resisted explanation, this shifts the question from how to slow scarring to where the scarring begins. The evidence is still animal evidence, and its meaning for human patients awaits the test of time and trial.
A team at UCLA Health has reported that a fat imbalance inside one type of lung immune cell may be able to start pulmonary fibrosis, rather than appearing only after the damage is done. The work was done in mice and centers on alveolar macrophages, the lung's first line of defense against pathogens and injury.
Under normal conditions, these cells help maintain and repair the airspaces. When their lipid handling goes wrong, they lose their protective role and begin pushing disease forward. Fat-laden macrophages had long been seen in fibrotic lungs, but they were usually read as a consequence of illness, not a cause.
The question grew out of earlier UCLA research showing that lipids in the lungs of patients with severe lung diseases tracked with disease burden and lost lung function. To test whether lipid buildup could trigger fibrosis, the researchers studied mice missing ABCG1, a protein that balances cholesterol in macrophages. Lipids built up quickly in those animals, before other biological changes appeared, and the lipids could signal fibroblasts to produce scar tissue.
When the team restored macrophages carrying ABCG1 through bone marrow transplantation, the mice were almost completely protected. The reverse experiment also held: normal mice given deficient marrow developed more fibrosis.
The timing matters most. Lipids accumulated while there was little or no scarring, suggesting the disease may begin earlier and in a different place than clinicians assumed. Today's treatments mostly slow an established disease, so the findings point toward protecting lipid handling in these cells, blocking harmful lipid uptake by fibroblasts, or detecting lipid changes early to identify those at risk.
Elizabeth Tarling of UCLA Health leads the study. The results have not yet been tested in people, and the key question now is whether the same sequence holds in human lungs.
A team at UCLA Health has reported that a fat imbalance inside one type of lung immune cell may be able to set pulmonary fibrosis in motion, rather than simply showing up after the damage is done. The work was done in mice, and it centers on alveolar macrophages, the cells that act as the lung's first line of defense against pathogens and tissue injury.
Under normal conditions, these macrophages help maintain and repair the airspaces of the lung. The new study describes what happens when their lipid handling goes wrong: they lose their protective qualities, malfunction, and begin actively promoting disease. Macrophages swollen with fat have long been seen in lungs affected by pulmonary fibrosis, but they were generally read as a consequence of the illness, not a cause.
The stakes are high because pulmonary fibrosis is debilitating and has few treatment options. It involves progressive scarring of lung tissue that ultimately leads to respiratory failure, and mortality is high. What triggers it has remained largely unsolved.
The question grew out of earlier UCLA work on cholesterol metabolism in macrophages. Those studies found that lipids detectable in the lungs of patients with other severe lung diseases, autoimmune pulmonary alveolar proteinosis and idiopathic pulmonary fibrosis, were directly associated with disease burden and reduced lung function. That prompted the researchers to ask whether lipid buildup might be one of the triggers of fibrosis.
To test it, they studied mice lacking ABCG1, a protein that manages cholesterol balance in macrophages. In these animals, lipids, cholesterol in particular, built up quickly in the alveolar macrophages, and this happened before other biological changes appeared in the lungs. The team then found that the lipids can signal directly to neighboring cells called fibroblasts, prompting them to activate and produce scar tissue. That gives a direct mechanistic link to fibrosis.
The researchers also tested whether fixing the problem could prevent disease. Using bone marrow transplantation, they transferred macrophages that carry ABCG1 back into the mice. With those cells restored, the animals were almost completely protected from fibrosis. The reverse experiment pointed the same way: giving otherwise normal mice bone marrow deficient in ABCG1 was enough to promote fibrosis.
A key finding is the order of events. Lipids began accumulating in the alveolar macrophages when there was minimal to no fibrosis, which changes how researchers and clinicians think about when and where the disease may begin. Current therapies mainly slow progression once fibrosis is established. The findings suggest two other routes: a treatment that protects or restores normal lipid handling in alveolar macrophages, or one that stops fibroblasts from taking up harmful lipids. A diagnostic route is also possible. If lipid changes can be detected in people at earlier stages, they might eventually help identify those at increased risk.
Elizabeth Tarling, a professor of cardiology in the department of medicine at UCLA Health, is the lead author. Co-authors are Elizabeth F. Redente, Isaiah Little, Marissa O'Callaghan, Lucas Dantas, Michelle Steel, Angela Cheng, Elinor Lee, Richard L. Watson, Kevin J. Williams, Michael P. Keane, James P. Bridges, Alexandra L. McCubbrey, Thomas Q. de Aguiar Vallim, and Cormac McCarthy. The results come from mice and have not yet been tested in humans, so the next step to watch is whether the same sequence holds in people.
Bemerkenswerte Zitate
Lipids began accumulating in alveolar macrophages when there was minimal to no fibrosis, changing how researchers think about when and where the disease begins.— UCLA Health study findings, as reported by News-Medical
Möchten Sie die ganze Geschichte?
Das Original lesen bei News-Medical ↗
Health & Medicine